Արկօքսիա

main_info

  • trade_name:
  • Արկօքսիա
  • dosage:
  • 90մգ(7/1x7/) բլիստերում, (28/4x7/) բլիստերում
  • pharmaceutical_form:
  • դեղահատեր թաղանթապատ
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Արկօքսիա
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

20-9-2018

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Health Canada's sampling and evaluation program has determined that the rubber animals do not meet the Canadian safety requirements for toys. The squeakers inside the rubber animals can be easily removed; these small parts pose a choking hazard to young children.

Health Canada

12-9-2018

FDA awards five grants to advance the development of pediatric medical devices

FDA awards five grants to advance the development of pediatric medical devices

FDA has awarded grants to five Pediatric Device Consortia that will provide advice to innovators of children's medical devices

FDA - U.S. Food and Drug Administration

22-2-2019

A5: #FDA funds $6M/yr for the Pediatric Device Consortia Grants Program – a program to provide advice and support services to advance innovation in medical devices for children.  http://go.usa.gov/cpygz  #NIHChat

A5: #FDA funds $6M/yr for the Pediatric Device Consortia Grants Program – a program to provide advice and support services to advance innovation in medical devices for children. http://go.usa.gov/cpygz  #NIHChat

A5: #FDA funds $6M/yr for the Pediatric Device Consortia Grants Program – a program to provide advice and support services to advance innovation in medical devices for children. http://go.usa.gov/cpygz  #NIHChat

FDA - U.S. Food and Drug Administration

9-11-2018

TGA presentation: Generic and Biosimilar Medicines Association (GBMA) meeting, 2 November 2018

TGA presentation: Generic and Biosimilar Medicines Association (GBMA) meeting, 2 November 2018

Short presentation on the ACSS Consortium, the Generic Medicines Working Group and the Generic Medicines Work-Sharing Trial

Therapeutic Goods Administration - Australia

31-7-2018

FDA’s Pediatric Device Consortia Grant Program (PDC) facilitates the development, of medical devices for children. 18 pediatric medical devices have been approved/cleared to date.  Learn more about the PDC here:  https://go.usa.gov/xUvBC  #Pediatrics #Med

FDA’s Pediatric Device Consortia Grant Program (PDC) facilitates the development, of medical devices for children. 18 pediatric medical devices have been approved/cleared to date. Learn more about the PDC here: https://go.usa.gov/xUvBC  #Pediatrics #Med

FDA’s Pediatric Device Consortia Grant Program (PDC) facilitates the development, of medical devices for children. 18 pediatric medical devices have been approved/cleared to date. Learn more about the PDC here: https://go.usa.gov/xUvBC  #Pediatrics #MedicalDevice #FDA pic.twitter.com/HgMSCIbmra

FDA - U.S. Food and Drug Administration

19-7-2018

Regulatory and procedural guideline:  Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Regulatory and procedural guideline: Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Critical Path Global Ltd.’s Critical Path for Parkinson’s (CPP) is a multinational consortium of the Critical Path Institute supported by Parkinson’s UK and industry. This broad collaboration of pharmaceutical companies, government agencies, academic institutions, and charities aims to accelerate the development of therapies for Parkinson’s disease (PD).

Europe - EMA - European Medicines Agency

5-7-2018

International work-sharing pilot - Apalutamide (Erlyand)

International work-sharing pilot - Apalutamide (Erlyand)

Apalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group

Therapeutic Goods Administration - Australia

14-6-2018

ACSS public statement, 27-28 October 2017

ACSS public statement, 27-28 October 2017

ACSS Consortium Generic Medicines Working Group public statement for Brazil meeting, October 2017

Therapeutic Goods Administration - Australia